STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31

Stoke Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$24.82+0.65 (+2.69%)

Close on Oct 19, 2026

Market cap: $1.64B
P/E (TTM): –
Dividend yield: –

Stoke Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	184	37	8.78	12	–	–	–	–
Research & Development	138	89	82	78	54	32	24	8.37
Selling, General & Admin	67	49	–	–	–	–	–	–
General & Administrative	–	49	41	39	32	21	12	4.41
Operating Expenses	205	138	124	117	86	53	36	13
Operating Income	-21	-101	-115	-104	-86	-53	-36	-13
Interest Expense	0.01	0.03	0.05	–	–	–	–	–
Interest & Investment Income	14	13	9.96	–	–	0.74	3.35	0.27
Other Non-Operating Income	14	12	10	3.29	0.26	0.80	3.35	0.26
Asset Impairment Charges	0	0	0	0	0	0	0	0
Gain (Loss) on Sale of Assets	-0.15	–	0.00	–	-0.03	0.00	0.00	-0.01
Income Tax Expense	0	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-6.89	-89	-105	-101	-86	-52	-32	-13
Net Income	-6.89	-89	-105	-101	-86	-52	-32	-13
EPS (Basic)(per share)	-0.12	-1.65	-2.38	-2.60	-2.34	-1.56	-1.80	-17.65
EPS (Diluted)(per share)	-0.12	-1.65	-2.38	-2.60	-2.34	-1.56	-1.80	-17.65
Shares Outstanding (Basic, Weighted)(shares)	59	54	44	39	37	33	18	0.71
Shares Outstanding (Diluted, Weighted)(shares)	59	54	44	39	37	33	18	0.71

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -809.7%
Net margin: -753.6%
Return on equity, FY2025: -2.4%

Financial strength

Current ratio: 7.69
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 262.4%

Valuation

P/E ratio: –
Price to sales: 59.39
Price to book: 4.74
Dividend yield: –